Clinical trials evaluating the potential applications of ctDNA in lung cancer screening
| Identifier | Methods | Initiator | Study type | Estimated enrollment, n | Observational model | Time perspective | Status/results |
|---|---|---|---|---|---|---|---|
| NCT04814407 | ctDNA methylation EMS-ddPCR scLSM-FACS | Taiwan University Hospital | Observational | 900 | Cohort | Prospective | Recruiting; estimated study completion date is December 31, 2027 |
| NCT04712877 | Genetic mutations NGS | Lung Cancer Research Foundation | Observational | 1,000 | Cohort | Prospective | Not yet recruiting; estimated study completion date is November 1, 2023 |
| NCT03651986 | ctDNA methylation NGS | AnchorDx Medical Co., Ltd. | Observational | 10,560 | Cohort | Prospective | Recruiting; estimated study completion date is June 2023 |
| NCT04253509 | ctDNA methylation sequencing | Samsung Medical Center | Observational | 280 | Cohort | Prospective | Recruiting; estimated study completion date is February 2022 |
| NCT03685669 | ctDNA methylation biomarkers | Shanghai Chest Hospital | Observational | 300 | Cohort | Cross-Sectional | Recruiting; estimated study completion date is December 2019 |
| NCT04698681 | Genetic mutations NGS | Calithera Biosciences. Inc | Interventional Clinical Trial | 200 | Single group assignment | Prospective | Active, not recruiting; estimated study completion date is May 2022 |
| NCT03181490 | ctDNA methylation, high-throughput bisulfite DNA sequencing, NGS | The First Affiliated Hospital of Guangzhou Medical University | Observational | 1,490 | Cohort | Cross-Sectional | Completed; detected early-stage lung cancer and differentiated lung cancers from benign pulmonary nodules |
| NCT02612350 | ctDNA genetic mutations | Pathway Genomics | Observational | 1,106 | Cohort | Prospective | Completed; provided a new way to investigate screening utility |
ctDNA, circulating tumor DNA; EMS-ddPCR, enriched methylation-specific droplet digital PCR; scLSM-FACS, single-cell, locus-specific methylation detection.